Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP2 | O95551 | 2/20 | 0.52 |
| ▸ | PNMT | P11086 | 6/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 10/20 | 0.38 |
| ▸ | ESR1 | P03372 | 9/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL481427 | 0.84 | TDP2 (0.55) | TDP2PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL481172 | 0.75 | ALDH1A1 (0.59) | TDP2ADRA2ANPC1MAPTRAB9A | |
| SCHEMBL783721 | 0.74 | TDP2 (0.45) | TDP2PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL4891220 | 0.74 | TDP2 (0.55) | TDP2PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL23166405 | 0.73 | TDP2 (0.46) | TDP2PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL14346526 | 0.73 | METAP1 (0.47) | TDP2PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL21841861 | 0.73 | TDP2 (0.46) | TDP2PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL5525788 | 0.73 | MAPT (0.62) | TDP2PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL2137121 | 0.73 | METAP1 (0.47) | TDP2PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL18454733 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124964-B2 | Field-effect transistor | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2012-02-28 | — | — | US | disclosed |
| US-20100032655-A1 | Field-effect transistor | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100032655-A1 | Field-effect transistor | CHRM1, TEAD1, XPO6 | TDP2 3835/4885PNMT 739/4885ADRA2A 2977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.